Core Viewpoint - Y-mAbs Therapeutics, Inc. is set to report its fourth quarter and full year 2024 results on March 4, 2025, indicating ongoing developments in its biopharmaceutical operations focused on cancer treatment [1][2]. Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3]. - The company utilizes advanced technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies from the Y-BiClone platform [3]. - Y-mAbs has a robust product pipeline, including DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma in specific patient conditions [3]. Upcoming Events - A conference call and webcast will be held on March 4, 2025, at 8:00 a.m. ET to discuss the financial results, with a live audio webcast available on the company's Investor Relations website [2].

Core Insights - Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment [3] Group 1: Company Overview - The company is known for its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform [3] - Y-mAbs has a broad and advanced product pipeline, including DANYELZA® (naxitamab-gqgk), which is the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after prior therapy [3] Group 2: Upcoming Events - Michael Rossi, President and CEO of Y-mAbs, will participate in a fireside chat at the Oppenheimer 35th Annual Life Sciences Conference on February 11, 2025, at 4:40 p.m. ET [1] - A live webcast of the event will be available on the company's investor relations website and will be archived for 30 days after the event [2]

Core Viewpoint - Y-mAbs Therapeutics, Inc. (YMAB) is experiencing significant selling pressure, with a 25.7% decline over the past four weeks, but is now positioned for a potential trend reversal due to being in oversold territory and positive earnings expectations from Wall Street analysts [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - YMAB has an RSI reading of 18.67, suggesting that heavy selling may be exhausting itself, indicating a potential bounce back towards equilibrium in supply and demand [5] Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for YMAB will improve, with a 2.6% increase in the consensus EPS estimate over the last 30 days [6] - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [6] Group 3: Analyst Ratings - YMAB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7]

Core Viewpoint - Y-mAbs Therapeutics, Inc. (YMAB) is experiencing significant selling pressure, with a 26.9% decline over the past four weeks, but is now positioned for a potential trend reversal due to being in oversold territory and positive earnings outlook from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to identify oversold stocks, with a reading below 30 indicating oversold conditions [2]. - YMAB's current RSI reading is 20.9, suggesting that the heavy selling may be exhausting, indicating a possible bounce back towards equilibrium [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that earnings estimates for YMAB will improve, with a 2.6% increase in the consensus EPS estimate over the last 30 days [6]. - An upward trend in earnings estimate revisions typically correlates with price appreciation in the near term [6]. Group 3: Analyst Ratings - YMAB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [7].

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of preclinical and translational pharmacokinetics (PK) data of GD2-SADA in a poster at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Mid-Winter and American Col ...

Company Overview - Y-mAbs Therapeutics (NASDAQ: YMAB) has been covered with increasing optimism throughout 2024, with a "Buy" sentiment being highlighted [1] - The company operates in the biotech sector, focusing on clinical trials and innovative treatments [1] Analyst Background - The analyst holds a PhD in biochemistry and has extensive experience in analyzing clinical trials and biotech companies [1] - The analyst's mission is to educate investors on the science behind biotech investments and help them conduct due diligence [1] Disclosure and Independence - The analyst has no stock, option, or derivative positions in Y-mAbs Therapeutics or any other mentioned companies [2] - The article expresses the analyst's independent opinions and is not influenced by compensation or business relationships with the mentioned companies [2] Platform Disclaimer - Seeking Alpha emphasizes that past performance does not guarantee future results and does not provide specific investment recommendations [3] - The platform's analysts are third-party authors, including both professional and individual investors, who may not be licensed or certified by regulatory bodies [3]

Core Insights - Y-mAbs Therapeutics, Inc. has established two business units focused on Radiopharmaceuticals and DANYELZA to enhance clinical development and commercial potential [3][4][5] - Preliminary data from the GD2-SADA Phase 1 trial indicates the tolerability and validity of the SADA PRIT platform, with data presentation expected in Q2 2025 [8][9] - The company reported an estimated unaudited total net revenue of approximately $88 million for FY 2024, aligning with its guidance range [10] - As of December 31, 2024, the company has approximately $67 million in cash and marketable securities, expected to support operations until 2027 [10] Business Update - The company is realigning operations by creating two business units: Radiopharmaceuticals and DANYELZA, aimed at optimizing resources and enhancing clinical execution [3][4] - The realignment is expected to improve capital efficiencies and align strategic priorities [5] Radiopharmaceuticals - The SADA PRIT platform aims to enhance traditional radioimmunotherapy by delivering high therapeutic doses while minimizing off-target exposure [6] - The platform is currently being evaluated in two clinical trials in the U.S. [6] DANYELZA - DANYELZA is the only FDA-approved treatment for high-risk relapsed/refractory neuroblastoma in patients aged one year and older, launched commercially in 2021 [6] Workforce Adjustment - The company anticipates a workforce reduction of up to approximately 13%, with some roles being relocated from Denmark to the U.S. [7] Pipeline Advancement - In the GD2-SADA Phase 1 trial, 21 patients have been dosed, showing no dose-limiting toxicities or treatment-related adverse events [8][9] - The company plans to dose the first patient in the CD38-SADA Phase 1 trial in Q1 2025 [9] Financial Results - Preliminary estimated unaudited total net revenue for FY 2024 is approximately $88 million, within the guidance range of $87 million to $95 million [10] - The estimated cash investment for FY 2024 is approximately $11 million, below the guidance range of $15 million to $20 million [10] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [12]

Core Insights - Y-mAbs Therapeutics, Inc. has announced the establishment of two business units aimed at accelerating the clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA [2][3][4] - Preliminary data from the GD2-SADA Phase 1 trial indicates the tolerability and validity of the SADA PRIT platform's pre-targeting approach, with data presentation expected in Q2 2025 [8][9] - The company reported preliminary estimated unaudited total net revenue of approximately $88 million for the year ended December 31, 2024, aligning with its guidance range [10] - As of December 31, 2024, the company has approximately $67 million in cash, cash equivalents, and marketable securities, which is expected to support operations into 2027 [10] Business Update - The company is realigning operations by creating two business units: Radiopharmaceuticals and DANYELZA, to enhance resource optimization and clinical development agility [3][4] - The realignment is expected to lead to a workforce reduction of up to approximately 13%, with some roles being moved from Denmark to the U.S. for better coordination [7] Radiopharmaceuticals - The SADA PRIT platform aims to improve traditional radioimmunotherapy by delivering high therapeutic doses while minimizing off-target exposure and reducing costs [6] - The platform is currently being evaluated in two clinical trials in the U.S. [6] DANYELZA - DANYELZA is the only FDA-approved treatment for patients aged one year and older with high-risk relapsed/refractory neuroblastoma, commercially launched in 2021 [6] Pipeline Advancement - In the GD2-SADA Phase 1 trial, 21 patients have been dosed, showing no dose-limiting toxicities or treatment-related adverse events [8][9] - The company anticipates dosing the first patient in the CD38-SADA Phase 1 trial in the first quarter of 2025 [9] Financial Overview - Preliminary estimated total cash investment for FY 2024 is approximately $11 million, below the guidance range of $15 million to $20 million [10] - The company plans to provide full-year 2025 guidance alongside the FY 2024 earnings report in Q1 2025 [13] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [12]

Company Leadership Changes - Sue Smith, Chief Commercial Officer, will be departing the organization [1] - Doug Gentilcore appointed as Senior Vice President, Head of DANYELZA Business Unit [4] - Doug Gentilcore brings over two decades of strategic leadership experience in the pharmaceutical industry [5] Product Information - DANYELZA® (naxitamab-gqgk) is indicated for the treatment of pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow [1] - DANYELZA® includes a Boxed Warning for serious infusion-related reactions and neurotoxicity [1] - DANYELZA is currently not approved for the treatment of osteosarcoma in any jurisdiction [2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic cancer products [3] - The Company's technologies include its investigational SADA PRIT Platform and bispecific antibodies generated using the Y-BiClone platform [3] - The Company's product pipeline includes the anti-GD2 therapy DANYELZA® [3] Future Plans and Expectations - Doug Gentilcore's experience is expected to be instrumental in the continued commercial expansion and growth of DANYELZA beyond pediatric oncology [5]

Core Insights - Y-mAbs Therapeutics, Inc. has established two business units focused on Radiopharmaceuticals and DANYELZA to enhance operational efficiency and commercial growth [2][3][4] - The company reported preliminary estimated unaudited total net revenue of approximately $88 million for the year ended December 31, 2024, aligning with its guidance range [9] - Y-mAbs anticipates a reduction in its workforce by up to 13% as part of its business realignment strategy [6] Business Update - The establishment of the two business units aims to optimize internal resources and enhance the advancement of the SADA PRIT platform while driving the commercial growth of DANYELZA [2][3] - The SADA PRIT platform is designed to improve traditional radioimmunotherapy by delivering high therapeutic doses with minimized off-target exposure [5] - DANYELZA is the only FDA-approved treatment for high-risk relapsed/refractory neuroblastoma in patients aged one year and older, launched commercially in 2021 [5] Pipeline Advancement - The GD2-SADA Phase 1 trial has dosed 21 patients, showing a well-tolerated pre-targeting approach with no dose-limiting toxicities reported [7][8] - The company expects to present data from Part A of the GD2-SADA Phase 1 trial in the second quarter of 2025 [12] - The first patient in the CD38-SADA Phase 1 trial is expected to be dosed in the first quarter of 2025 [8][12] Financial Overview - Preliminary estimated unaudited cash, cash equivalents, and marketable securities as of December 31, 2024, are approximately $67 million, expected to support operations into 2027 [9] - The total cash investment for the full year 2024 is estimated at approximately $11 million, below the company's guidance range [9] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [11] - Full year 2025 guidance is expected to be provided alongside the full year 2024 earnings report in the first quarter of 2025 [12]